The Oncology Institute, Inc.

TOI

US68236X1000

Healthcare Facilities & Services

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.06 ^USD	-2.75%		-11.67%	-48.04%

Apr. 08	The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer	CI
Apr. 04	The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California	CI

The Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023

November 08, 2023 at 04:05 pm EST

The Oncology Institute Reported goodwill impairment charge of $17 million in the nine months ended 2023 that did not occur in the same period of 2022.

Latest news about The Oncology Institute, Inc.

The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer	Apr. 08	CI
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California	Apr. 04	CI
Transcript : The Oncology Institute, Inc., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
The Oncology Institute Q4 Loss Widens, Revenue Increases	Mar. 27	MT
(TOI) THE ONCOLOGY INSTITUTE Forecasts Fiscal Year 2024 Revenue Range $400M - $415M	Mar. 27	MT
Earnings Flash (TOI) THE ONCOLOGY INSTITUTE Posts Q4 Revenue $85.8M	Mar. 27	MT
The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024	Mar. 27	CI
The Oncology Institute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 26	CI
MaxHealth & The Oncology Institute, Inc. Expand Value-Based Care Partnership	Mar. 14	CI
The Oncology Institute Expands Its Specialty Medication Business by Opening Pharmacy Operations in California	Dec. 04	CI
Oncology Institute Insider Sold Shares Worth $118,581, According to a Recent SEC Filing	Nov. 16	MT
Transcript : The Oncology Institute, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Tranche Update on The Oncology Institute, Inc.'s Equity Buyback Plan announced on August 30, 2023.	Nov. 08	CI
Tranche Update on The Oncology Institute, Inc.'s Equity Buyback Plan announced on June 15, 2023.	Nov. 08	CI
The Oncology Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (TOI) TOI MANAGEMENT LLC Reports Q3 Revenue $82M, vs. Street Est of $74.7M	Nov. 08	MT
The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Year 2023	Nov. 08	CI
The Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023	Nov. 08	CI
The Oncology Institute, Inc. Names Jeremy Castle as Chief Operations Officer	23-10-11	CI
The Oncology Institute Appoints Jeremy Castle as Chief Operations Officer	23-10-11	MT
The Oncology Institute Regains Compliance With Nasdaq's Minimum Closing Bid Price Rule	23-09-18	MT
The Oncology Institute, Inc. Appoints Jeremy N. Castle as Chief Operations Officer	23-09-06	CI
The Oncology Institute, Inc. Announces Resignation of Ravi Sarin as Member of the Board of Directors and Committees	23-09-01	CI
Oncology Institute to Buy Back 2 Million Shares	23-08-30	DJ
The Oncology Institute, Inc. announces an Equity Buyback for 2,000,000 shares, for $2 million.	23-08-30	CI

Chart The Oncology Institute, Inc.

Duration

Period

More charts

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Sector

Healthcare Facilities & Services

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.12 USD

Average target price

2.5 USD

Spread / Average Target

+123.21%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
THE ONCOLOGY INSTITUTE, INC.	-48.04%	78.77M
CVS HEALTH CORPORATION	-28.69%	85.35B
HCA HEALTHCARE, INC.	+14.32%	81.95B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	28.99B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.43%	16.98B
FRESENIUS SE & CO. KGAA	-0.36%	16.85B
QUEST DIAGNOSTICS INCORPORATED	-0.24%	15.35B
FRESENIUS MEDICAL CARE AG	+4.32%	12.42B
DAVITA INC.	+33.40%	12.19B
PURE HEALTH HOLDING	-31.40%	11.89B

Other Healthcare Facilities & Services

The Oncology Institute, Inc.

Equities

TOI

US68236X1000

Healthcare Facilities & Services

The Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023

Latest news about The Oncology Institute, Inc.

Chart The Oncology Institute, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Other Healthcare Facilities & Services